NLRP3 inflammasome is an intracellular complex consisting of the sensor (NLRP3), the adaptor (ASC), and the effector (Caspase-1). The NLRP3 inflammasome activation promotes the release of pro-inflammatory factors (IL-1ß and IL-18, dependent on Caspase-1) and Gasdermin D-mediated pyroptotic cell death. The activation of NLRP3 inflammasome has two steps: priming and activation. Several metabolites, including islet amyloid polypeptide, cholesterol, monosodium, Amyloid ß, and a-synuclein, have been reported to involve in NLRP3 inflammasome activation.
Thus, it is rational to speculate that targeting NLRP3 inflammasome may be the ideal target for metabolic disease intervention.
At present, plenty of drugs targeting NLRP3 inflammasome have been proved to have a good effect on metabolic diseases, such as Anakinra (IL-1 receptor antagonist) and Atorvastatin (inhibits TLR4/MyD88/NF-?B dependent NLRP3 expression), Allopurinol (reducing uric acid concentration).
This Research Topic aims to explore the scientific research and review articles that report the milestones achieved in the field of NLRP3 inflammasome in metabolic diseases. A better understanding of the new mechanism for NLRP3 inflammasome activation may uncover new therapeutic targets for metabolic diseases. Furthermore, the discovery of new compounds, single compounds from the natural product, or extended therapeutic application of the approved drugs will also provide new possibilities for metabolic disease treatment. Additionally, the design of the new delivery methods or new nanoformulations enhancing the efficacy or weakening the adverse effects of the existing drugs and clinical research about the drugs targeting NLRP3 inflammasome is also welcomed.
The main goal of this research topic is to bring more insight into the connection between NLRP3 inflammasome and metabolic diseases. Original research, reviews, systematic reviews, and case studies are welcomed for submission to this research topic.
We welcome studies (original research, reviews, metanalyses, case studies), but are not limited to, the following topics:
• New mechanism for NLRP3 inflammasome activation in metabolic diseases
• The discovery of new metabolites for NLRP3 inflammasome activation in metabolic diseases
• Omics or multi-omics study of NLRP3 inflammasome activation in metabolic diseases
• Clinical research of candidate compounds targeting NLRP3 inflammasome in metabolic diseases
• New materials and new delivery methods to enhance the efficacy of the existing drugs targeting NLRP3 inflammasome activation
• Discovery of new drugs, including single compounds from the natural product that affects NLRP3 inflammasome activation in metabolic diseases
This Research Topic does not accept publication studies carried out with crude extracts or mixtures. Only the use of highly purified, chemically characterized compounds is acceptable.
NLRP3 inflammasome is an intracellular complex consisting of the sensor (NLRP3), the adaptor (ASC), and the effector (Caspase-1). The NLRP3 inflammasome activation promotes the release of pro-inflammatory factors (IL-1ß and IL-18, dependent on Caspase-1) and Gasdermin D-mediated pyroptotic cell death. The activation of NLRP3 inflammasome has two steps: priming and activation. Several metabolites, including islet amyloid polypeptide, cholesterol, monosodium, Amyloid ß, and a-synuclein, have been reported to involve in NLRP3 inflammasome activation.
Thus, it is rational to speculate that targeting NLRP3 inflammasome may be the ideal target for metabolic disease intervention.
At present, plenty of drugs targeting NLRP3 inflammasome have been proved to have a good effect on metabolic diseases, such as Anakinra (IL-1 receptor antagonist) and Atorvastatin (inhibits TLR4/MyD88/NF-?B dependent NLRP3 expression), Allopurinol (reducing uric acid concentration).
This Research Topic aims to explore the scientific research and review articles that report the milestones achieved in the field of NLRP3 inflammasome in metabolic diseases. A better understanding of the new mechanism for NLRP3 inflammasome activation may uncover new therapeutic targets for metabolic diseases. Furthermore, the discovery of new compounds, single compounds from the natural product, or extended therapeutic application of the approved drugs will also provide new possibilities for metabolic disease treatment. Additionally, the design of the new delivery methods or new nanoformulations enhancing the efficacy or weakening the adverse effects of the existing drugs and clinical research about the drugs targeting NLRP3 inflammasome is also welcomed.
The main goal of this research topic is to bring more insight into the connection between NLRP3 inflammasome and metabolic diseases. Original research, reviews, systematic reviews, and case studies are welcomed for submission to this research topic.
We welcome studies (original research, reviews, metanalyses, case studies), but are not limited to, the following topics:
• New mechanism for NLRP3 inflammasome activation in metabolic diseases
• The discovery of new metabolites for NLRP3 inflammasome activation in metabolic diseases
• Omics or multi-omics study of NLRP3 inflammasome activation in metabolic diseases
• Clinical research of candidate compounds targeting NLRP3 inflammasome in metabolic diseases
• New materials and new delivery methods to enhance the efficacy of the existing drugs targeting NLRP3 inflammasome activation
• Discovery of new drugs, including single compounds from the natural product that affects NLRP3 inflammasome activation in metabolic diseases
This Research Topic does not accept publication studies carried out with crude extracts or mixtures. Only the use of highly purified, chemically characterized compounds is acceptable.
